Phase 3 Stroke Trial, Recruiting NCT06749834 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06749834
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are showing signs of an acute stroke caused by a blocked blood vessel, where the stroke started within the last 24 hours, or who woke up with stroke symptoms (if the midpoint of their sleep was within the last 24 hours)
  • People whose stroke started between 4.5 and 24 hours ago and who meet specific treatment guidelines for clot-dissolving therapy (confirm with trial site)
  • People who took a newer type of blood thinner (such as apixaban, rivaroxaban, or dabigatran) between 4 and 48 hours before the stroke started
  • People aged 18 or older
  • People for whom informed consent has been obtained, as required by local ethics rules

Who may not be able to join:

  • People who are planned to have a procedure to physically remove or unblock the clot through a blood vessel
  • People whose blood clotting test result (APTT) is above 40 seconds
  • People who had significant physical disability before the stroke (a pre-stroke disability score above 2 on a standard scale)
  • People who have bleeding inside the skull or brain, including any type of brain or spinal bleed
  • People who have a previous history of bleeding inside the brain
  • People who experienced a serious head injury or stroke in the last 3 months
  • People who have a brain tumour or a very large brain aneurysm
  • People who had brain or spinal surgery in the last 3 months
  • People who had major surgery in the last 2 weeks
  • People who had bleeding in the stomach, bowel, or urinary tract in the last 3 weeks
  • People who are currently bleeding internally in an organ
  • People who have a tear in the main artery leaving the heart (aortic dissection)
  • People who had a needle inserted into an artery in the last week in a location that is difficult to apply pressure to stop bleeding
  • People with very high blood pressure (top number 180 mmHg or higher, or bottom number 100 mmHg or higher)
  • People with a tendency to bleed, including a low platelet count (below 100 × 10⁹/L) or similar conditions
  • People who received a low-molecular-weight heparin blood thinner injection in the last 24 hours
  • People taking warfarin (an older blood thinner) with certain blood test results above set limits (INR above 1.7 or PT above 15 seconds)
  • People whose blood sugar level is either too low (below 2.8 mmol/L) or too high (above 22.22 mmol/L)
  • People whose brain scan shows a large area of stroke damage (covering one-third or more of a major brain region called the middle cerebral artery territory)
  • People excluded based on the treating doctor's clinical judgement

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 8613958007213

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
27 January 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Excellent recovery assessed by the ratio of modified Rankin Scale (mRS) score of 0-1 (%) at 90 ± 7 days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov